ReviewInternational journal of molecular sciences2021
Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial.Hepatology communications · 2024Trial
- Efficacy of different nutrition interventions on sarcopenia in patients with cirrhosis: a systematic review and network meta-analysis.BMC nutrition · 2025Article
- Osteosarcopenia: epidemiology, molecular mechanisms, and management.Frontiers in endocrinology · 2025Review
- The association of HALP score with low muscle mass in older adults.Frontiers in nutrition · 2025Article
- Improvement of Physical Functions in Elderly Patients with Heart Failure Depends on the Hepatic Reserve.Physical therapy research · 2025Article
- Impact of Glucose Profile, Fasting Insulin, and Renal Function on Sarcopenia in Elderly at Single Centered Nursing Home: A Cross-Sectional Structural Equation Model Analysis.Journal of multidisciplinary healthcare · 2025Article
- Validating the prognostic value of muscle changes in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt.Hepatobiliary surgery and nutrition · 2024Article
- Longitudinal changes in sarcopenia was associated with survival among cirrhotic patients.Frontiers in nutrition · 2024Article
- What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?Life (Basel, Switzerland) · 2023Review
- Sarcopenia in chronic viral hepatitis: From concept to clinical relevance.World journal of hepatology · 2023Review
- Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties.World journal of gastroenterology · 2023Review
- Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy.International journal of molecular sciences · 2023Article
- Nutritional Support for Alcoholic Liver Disease.Nutrients · 2023Review
- The adverse impact, assessment and management of sarcopenia in liver transplantation candidates and recipients.Hepatobiliary surgery and nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and strength that occurs with aging or in association with various diseases. The condition is prevalent worldwide and occurs more frequently in patients with chronic diseases owing to the intrinsic relationship of muscles with glucose, lipid, and protein metabolism. Liver cirrhosis is characterized by the progression of necro-inflammatory liver diseases, which leads to fibrosis, portal hypertension, and a catabolic state, which causes loss of muscle tissue. Sarcopenia is of significant concern in the state of liver cirrhosis because sarcopenia has been associated with higher mortality, increased hospital admissions, worse post-liver transplant outcomes, decreased quality of life, and increased risk for other complications associated with cirrhosis. Therefore, sarcopenia is also an important feature of liver cirrhosis, representing a negative prognostic factor and influencing mortality. An increased understanding of sarcopenia could lead to the development of novel therapeutic approaches that could help improve the cognitive impairment of cirrhotic patients; therefore, we present a review of the mechanisms and diagnosis of sarcopenia in liver disease and existing therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.